医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Major Korean Company Purchases Spire’s Advanced Simulator and EL Test Equipment for a Highly Automated PV Module Manufacturing Facility

2013年12月18日 AM07:25
このエントリーをはてなブックマークに追加


 

BEDFORD, Mass.

Spire Corporation (OTCQB: SPIR), a global solar company providing capital equipment and turn-key manufacturing lines to produce photovoltaic (“PV”) modules and optoelectronics thin film services, announced today that a major Korean company has purchased Spire’s Advanced Test and Metrology equipment including Simulator and Electroluminescence (“EL”) Test equipment for a highly automated module manufacturing facility.

Initial production volume will be 100 megawatts (“MW”) of high-efficiency crystalline silicon (“c-Si”) modules. In addition, implementation of a phased production plan is expected to produce over 400MW of c-Si modules supporting the demand for utility-scale power installations. The manufacturing facility is a highly automated inline factory including manufacturing execution systems communications, material identification, and integrated tracking over the entire production line. Spire is providing the process and technical expertise to integrate the multiple Simulator and EL Test equipment. Initial production is planned to fulfill installation requirements in early 2014.

Mr. Roger G. Little, Chairman and Chief Executive Officer, said, “We are very excited about the initial project and our long-term relationship as the manufacturing facility ramps its production volume over the next few years.”

About Spire Corporation

Spire Corporation is a global solar company providing technology, equipment and turn-key production lines to manufacture PV modules and providing optoelectronics thin film services. For further details on the Company and its products, please visit www.spirecorp.com.

Certain matters described in this press release including those relating to Spire’s prospects for growth constitute forward-looking statements under the federal securities laws. The discussion of forward-looking information requires management of the Company to make certain estimates and assumptions regarding the Company’s strategic duration and the effect of such plans on the Company’s financial results. Forward-looking statements contained in the press release speak only as of the date of this release. Subsequent events or circumstances occurring after such date may render these statements incomplete or out of date. The Company undertakes no obligation and expressly disclaims any duty to update such statements.

CONTACT

Spire Corporation
Roger G. Little, 781-275-6000
Chairman & CEO

同じカテゴリーの記事 

  • Poxel Provides a Financial Update for the First Quarter 2024 and Announces the Postponement of its 2023 Full-Year Results Release
  • ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)